



1/13




FIG. 1




FIG. 2

2/13




FIG. 3




FIG. 4

3/13




FIG. 5




FIG. 6

4/13




FIG. 7





FIG. 8

5/13



6/13




FIG. 10




FIG. 11

7/13




FIG. 12




FIG. 13

8/13




FIG. 14




FIG. 15



9/13

**Solubility Enhancement, Nano vs Raw MGA**




FIG. 16




FIG. 17

10/13




FIG. 18




FIG. 19

11/13




FIG. 20

12/13

**Physical Properties of Various Saturated Fatty Acids**

<i>Fatty Acid</i>	<i>Melting temperature (°C)</i>	<i>Solubility in water at 20°C(mg/g)</i>
<i>Caproic acid (C6)</i>	-3.4	10.82
<i>Caprylic acid (C8)</i>	16.7	0.68
<i>Capric acid (C10)</i>	31.4	0.15
<i>Lauric acid (C12)</i>	44	Insoluble
<i>Myristic acid (C14)</i>	58.5	
<i>Palmitic acid (C16)</i>	63-64	Insoluble
<i>Stearic acid (C18)</i>	69-70	Very slightly soluble

**FIG. 21**

**Composition of Dosage Megastrol Acetate Formulations  
of Dosage Forms Used in Multi-arm PK Study**

	<i>Formulation</i>
<i>Megace Tablet (20mg)</i>	<i>Unknown</i>
<i>IR SES (10mg) x2</i>	<i>MA/Pluronic F108/Capric Acid/Cremophor EL (1.77/0.83/48.7/48.7, wt%)</i>
<i>Controlled Release SES (10mg) x2</i>	<i>MA/Pluronic F108/Capric Acid/Cremophor EL (1.77/0.83/48.7/48.7, wt%)</i>
<i>4% Nanosuspension Hard-cap (20 mg)</i>	<i>MA/Pluronic F108/Capric Acid/Cremophor EL (3.8/1.4/47.4/47.4, wt%)</i>
<i>16% Nanosuspension Hard-cap (20 mg)</i>	<i>MA/Pluronic F108/Capric Acid/Cremophor EL (16.0/4.2/39.9/39.9, wt%)</i>

**FIG. 22**

**13/13**

***Plasma Sample Analysis (LC-MS) Conditions***

<b><i>HPLC Conditions</i></b>	<b><i>HPLC: Agilent 1100 (ID: LC-125) Column: MetaChem Polaris C18-A, 100x30mm, 3um. Guard Column: Metaguard Polaris C18-A, 4.6mm, 3um. Flow Rate: 0.35ml/min. Injection Volume: 40ul. Mobile Phase: Isocratic 60/40 CH<sub>3</sub>CN/H<sub>2</sub>O, 0.2% Formic Acid.</i></b>
<b><i>MS Conditions</i></b>	<b><i>MS: PE Sciex API 300 LC/MA/MA with Analyst Ion Source: TurbolonSpray Scan Type: Positive MRM. Curtain Gas: Nitrogen, 9. Nebulizer Gas: Nitrogen, 9. Ionspray Voltage: 5.0 kV. Declustering Potential: 22V. Collision Gas: Nitrogen, 2. Collision Energy: 15V. MRM: m/z 385.2 to 325.2 for MA, 400ms. M/z 315.1 to m/z 109.0 for internal standard, 400ms.</i></b>

**FIG. 23**